Bone marrow transplant in Ph+ ALL patients.

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Conventional chemotherapy offers a poor prognosis for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
• Allogeneic bone marrow transplantation (BMT) demonstrates improved outcomes, potentially due to high-dose chemotherapy and graft-versus-leukemia effects.
• Limited availability of matched related donors and patient eligibility issues (age, fitness) restrict BMT options.

Purpose of the Study:

• To review treatment strategies for Ph+ ALL, focusing on BMT and alternative approaches.
• To evaluate the role of matched unrelated donor (MUD) transplants and autologous stem cell transplantation (ASCT).
• To explore the potential of tyrosine kinase inhibitors like Imatinib in conjunction with transplantation.

Main Methods:

• Review of existing literature on BMT, MUD transplants, ASCT, and chemotherapy for Ph+ ALL.
• Discussion of treatment stratification based on patient age, donor availability, and fitness for conventional BMT.
• Consideration of novel therapeutic agents, including tyrosine kinase inhibitors, for pre- and post-transplant management.

Main Results:

• Allogeneic BMT, particularly sibling-matched, offers better outcomes than chemotherapy for Ph+ ALL.
• MUD transplants are an option for young patients without matched donors; ASCT or low-intensity MUD transplants are considered for older patients.
• The efficacy of ASCT versus chemotherapy remains debated; Imatinib may enhance transplant outcomes.

Conclusions:

• Treatment decisions for Ph+ ALL require careful consideration of donor availability, patient age, and fitness.
• Low-intensity allografts are under investigation and may offer a curative option for older patients ineligible for conventional BMT.
• Optimizing BMT strategies and integrating novel therapies are crucial for improving Ph+ ALL patient survival.